Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

309

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

SIIL LAIV (live, trivalent seasonal influenza vaccine)

Dose: 0.5 mL, The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season

BIOLOGICAL

Placebo

Inactive placebo will be identical to SII LAIV in appearance, ingredients, and concentrations, except it will be missing attenuated influenza virus.

Trial Locations (1)

Unknown

ICDDR,B Kamalapur, Dhaka

All Listed Sponsors
collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

collaborator

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER

lead

PATH Vaccine Solutions

OTHER

NCT01625689 - Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine | Biotech Hunter | Biotech Hunter